Literature DB >> 12204697

Ocular and systemic pharmacokinetics of latanoprost in humans.

Birgitta Sjöquist1, Johan Stjernschantz.   

Abstract

The ocular pharmacokinetics of latanoprost (13,14-dihydro-17-phenyl-18, 19,20-trinor-PGF(2alpha)-isopropyl ester; Xalatan [Pharmacia-Upjohn, Peapack, NJ]) was studied in patients undergoing cataract surgery using radio-immunoassay, and the systemic pharmacokinetics of latanoprost was studied in healthy human volunteers with 3H-latanoprost as well as radioimmunoassay. After topical application, latanoprost was rapidly hydrolysed in the cornea and blood. The maximum concentration of the active drug, latanoprost acid, was detected in the aqueous humor 1-2 hours after topical administration of the clinical dose and amounted to 15-30 ng/ml. The half-life of latanoprost acid in the aqueous humor was 2-3 hours. In the systemic circulation the peak concentration of latanoprost acid appeared 5 minutes after topical application and reached a level of 53 pg/ml with an elimination half-life of 17 minutes. In patients that had been on the drug continuously for more than 1 year, 5 out of 10 had plasma levels of latanoprost acid below the limit of detection (<30 pg/ml). The mean plasma clearance was 0.40 +/- 0.04 l/h. kg, and the volume of distribution was 0.16 +/- 0.02 l/kg after intravenous administration. The corresponding figures after ocular administration were 0.88 l/h. kg, and 0.36 l/kg. The majority of the radioactivity was recovered in urine (88%) and the rest was found in feces. In the eye the main metabolism of latanoprost was the ester hydrolysis. The only prominent chromatographic peak in plasma corresponded to latanoprost acid. In urine no latanoprost or latanoprost acid was detected. Before excretion latanoprost acid was beta oxidized to 1,2-dinor and 1,2,3,4-tetranor latanoprost acid. These metabolites accounted for approximately 66% of the radioactivity in urine. In conclusion, latanoprost is rapidly hydrolyzed in the eye and blood to latanoprost acid. Minimal further metabolism occurs in the eye, but latanoprost acid undergoes beta oxidation and other metabolism outside the eye. After topical application the peak concentration in aqueous humor was approximately 10(-7) M, whereas that in plasma was about 10(-10) M or less.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12204697     DOI: 10.1016/s0039-6257(02)00302-8

Source DB:  PubMed          Journal:  Surv Ophthalmol        ISSN: 0039-6257            Impact factor:   6.048


  29 in total

Review 1.  Prodrug strategies in ocular drug delivery.

Authors:  Megha Barot; Mahuya Bagui; Mitan R Gokulgandhi; Ashim K Mitra
Journal:  Med Chem       Date:  2012-07       Impact factor: 2.745

Review 2.  Pharmacotherapy and Adherence Issues in Treating Elderly Patients with Glaucoma.

Authors:  David C Broadway; Heidi Cate
Journal:  Drugs Aging       Date:  2015-07       Impact factor: 3.923

3.  Effect of latanoprost/timolol and dorzolamide/tiomolol on intraocular pressure after phacoemulsification surgery.

Authors:  Haydar Erdogan; Ayse Vural Ozec; Cengiz Caner; Mustafa Ilker Toker; Mustafa Kemal Arici; Aysen Topalkara
Journal:  Int J Ophthalmol       Date:  2011-04-18       Impact factor: 1.779

4.  [Original preparations versus generics--latanoprost: how similar is different?].

Authors:  M A Leitritz; H-P Lipp; B Voykov; F Ziemssen
Journal:  Ophthalmologe       Date:  2015-02       Impact factor: 1.059

5.  In vivo performance of a drug-eluting contact lens to treat glaucoma for a month.

Authors:  Joseph B Ciolino; Cristina F Stefanescu; Amy E Ross; Borja Salvador-Culla; Priscila Cortez; Eden M Ford; Kate A Wymbs; Sarah L Sprague; Daniel R Mascoop; Shireen S Rudina; Sunia A Trauger; Fabiano Cade; Daniel S Kohane
Journal:  Biomaterials       Date:  2013-10-04       Impact factor: 12.479

6.  Prostaglandins increase trabecular meshwork outflow facility in cultured human anterior segments.

Authors:  Cindy K Bahler; Kyle G Howell; Cheryl R Hann; Michael P Fautsch; Douglas H Johnson
Journal:  Am J Ophthalmol       Date:  2007-11-07       Impact factor: 5.258

7.  A survey of preoperative blood tests in primary open-angle glaucoma patients versus cataract surgery patients.

Authors:  Laura P Cohen; Jessica Wong; Aliya Z Jiwani; Scott H Greenstein; Stacey C Brauner; Sherleen C Chen; Angela V Turalba; Teresa C Chen; Lucy Shen; Douglas J Rhee; Janey L Wiggs; Jae Hee Kang; Stephanie Loomis; Louis R Pasquale
Journal:  Digit J Ophthalmol       Date:  2014-06-30

8.  Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension.

Authors:  Anne J Lee; Peter McCluskey
Journal:  Clin Ophthalmol       Date:  2010-07-30

9.  Effect of Cromakalim Prodrug 1 (CKLP1) on Aqueous Humor Dynamics and Feasibility of Combination Therapy With Existing Ocular Hypotensive Agents.

Authors:  Uttio Roy Chowdhury; Tommy A Rinkoski; Cindy K Bahler; J Cameron Millar; Jacques A Bertrand; Bradley H Holman; Joseph M Sherwood; Darryl R Overby; Kristen L Stoltz; Peter I Dosa; Michael P Fautsch
Journal:  Invest Ophthalmol Vis Sci       Date:  2017-11-01       Impact factor: 4.799

10.  Bimatoprost, prostamide activity, and conventional drainage.

Authors:  Zhou Wan; David F Woodward; Clive L Cornell; Hans G Fliri; José L Martos; Simon N Pettit; Jenny W Wang; Alexander B Kharlamb; Larry A Wheeler; Michael E Garst; Kari J Landsverk; Craig S Struble; W Daniel Stamer
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-09       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.